- Home >
- Institut Curie News >
- One Biosciences, a spin-off from Institut Curie, raises €15 million to revolutionize precision medicine
One Biosciences, a spin-off from Institut Curie co-founded with Home Biosciences in 2020, has raised €15 million from leading global investors. Born out of the pioneering work of Dr. Céline Vallot, research team leader at Institut Curie, the start-up harnesses the power of single-cell sequencing combined with artificial intelligence to personalize treatment for each patient. These funds will enable One Biosciences to accelerate the development of its platform, making precision medicine a clinical reality.
Co-founded in 2020 by Institut Curie and Home Biosciences, One Biosciences is a techbio company specializing in precision oncology. Building on the innovative research of Dr. Céline Vallot, CNRS research director and head of the “Dynamics of Epigenetic Plasticity in Cancer” team at Institut Curie, the start-up uses single-cell profiling to improve cancer diagnosis and guide therapeutic decisions. Supported since 2019 as part of Institut Curie’s incubation program, One Biosciences has received tailored guidance, from its earliest stages through its operational development.
Dr Cécile Campagne Director of Institut Curie’s Technology Transfer Office and Deputy Director of Carnot Curie Cancer
Combining single-cell technologies and AI to decode tumor heterogeneity
One Biosciences is tackling one of the most significant challenges in oncology: tumor heterogeneity. By combining advanced expertise in molecular biology and AI, the company creates comprehensive functional profiles of individual patients' tumors, decoding the complex biology behind treatment resistance in advanced cancers.
One Biosciences’ single-cell technologies and AI-driven analytics deliver high-resolution omics1 profiling to support precise patient selection, therapy development, optimized treatment strategies, and clinical trial matching.
"One Biosciences was founded on the belief that we can guide each patient's treatment decisions by bringing single-cell analysis into routine clinical practice. We are now close to making that vision a reality: beginning in 2025, the first high-resolution profiles will be sent to physicians in less than two weeks. We hope to change the lives of many patients in the long term," said Dr Céline Vallot.
Significant fundraising to transform cancer diagnosis and treatment
One Biosciences has completed its Series A funding round, raising €15 million from global investors . This investment will accelerate the development and clinical validation of OneMap™, the company’s flagship diagnostic platform that integrates single-cell analysis and AI. Designed for use with routine tumor biopsy samples, OneMap™ enables clinicians to make data-driven treatment decisions in as little as two weeks. It will be validated in real-world studies and benchmarked against existing diagnostic solutions across multiple indications in Europe and the United States.
The funding will also support strategic partnerships with pharmaceutical and biotech companies looking to integrate OneCure™, One Biosciences’ proprietary single-cell offering, into their drug development and clinical trial pipelines.
Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to transform our groundbreaking technology into real-time results that will impact drug development and, ultimately, patient care. The extraordinary support we’ve received from a group of leading global investors strengthens our conviction and will accelerate our path to market.”
David Schilansky and Magali Richard, co-founders of Home Biosciences and One Biosciences, stated: “When we co-founded Home Biosciences, our mission was to build companies that would become market leaders. We believe that One Biosciences has already exceeded that ambition and will be a game-changer in precision oncology—on a paradigm-shifting scale. This new milestone validates this exciting journey.”
[1] “Omics” sciences capture large-scale biological data across various cellular levels—from DNA (genomics) and gene expression (transcriptomics) to protein production (proteomics) and cellular metabolism (metabolomics).
[2] The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Partners.
